Feng Liu,1,
Suna Cai,1
Xiaoqin Lin,1
Aihua Li,1
Yumay Chen,2
Bingnan Gu,1
Eva Y.-H. P. Lee,1 and
Wen-Hwa Lee1*
Department of Biological Chemistry, College of Medicine, University of California, Irvine, Irvine, California 92697,1 Department of Medicine, University of Texas Health Science Center at San Antonio, San Antonio, Texas 782452
Received 16 November 2004/ Returned for modification 25 December 2004/ Accepted 3 February 2005
| ABSTRACT |
|---|
|
|
|---|
| INTRODUCTION |
|---|
|
|
|---|
CtIP is an 897-amino-acid protein that is ubiquitously expressed in different types of cells (8, 42). Apart from specific motifs used to bind Rb (LECEE) and CtBP (PLDLS), two coiled-coil domains of CtIP are also recognized. The one at the N terminus is used for homodimerization of CtIP (7). Interestingly, judging by sequence similarity, the CtIP gene so far has only been found in higher eukaryotic organisms, including Homo sapiens, Mus musculus, and Rattus norvegicus, with significant sequence divergence, implying a late participation during evolution.
The interaction between CtIP and CtBP is believed to play an important role in the CtIP-mediated and CtBP-dependent transcriptional repression. CtBP, identified as a C-terminal binding protein of human adenovirus E1A protein (2, 33), could function as a transcriptional corepressor in a histone deacetylase (HDAC)-dependent or -independent manner and may play critical roles during the early development and oncogenesis (3). Like CtBP, CtIP also possesses transcriptional repression activity when artificially fused to GAL4 DNA binding domain and coexpressed with reporter gene driven by a simian virus 40 promoter with upstream GAL4 binding sites (27). On the other hand, Rb family proteins bind CtIP at the LECEE motif, and mutation of this site disrupts their interaction. Using the same transcription reporter assay, mutations of the binding domain of Rb prevent the association of CtIP and fail to repress transcription (27). However, it remains unclear whether binding of CtIP to Rb has a role other than transcriptional repression.
In addition to Rb family proteins, BRCA1 can also physically and functionally interact with CtIP/CtBP complex. The N-terminal 133 to 369 amino acids of CtIP mediate its interaction with the C-terminal repeats (BRCT) of BRCA1 (42, 45). Significantly, tumor-associated mutations in BRCT domains abolish this specific interaction (22, 42, 46). DNA damage agents such as ionizing irradiation induce the hyperphosphorylation of CtIP at serine 664 and 745 by ATM kinase (23). And this event is suggested to modulate BRCA1 for the transcriptional activation of p21 and GADD45 upon DNA damage (22, 23), although the detailed mechanism remains to be clarified.
Ikaros family proteins are transcriptional repressors, which can interact with the HDAC-recruiting factors, Sin3 and Mi-2b, and exhibit HDAC-dependent repression activity (20). In addition, Ikaros can also directly bind to CtBP, Rb, and CtIP, which can interact with the basal transcription factor TFIIB (19). That may explain how Ikaros repression works through an HDAC-independent pathway.
Those observations deduced from studies of other proteins suggest that CtIP serves as a corepressor for transcriptional repression. However, the actual biological function of CtIP remains unclear. Especially, systematic study of CtIP loss of function has not been reported yet. In this communication, we show that the Ctip/ embryos die at embryonic day 4.0 (E4.0) as blastocysts fail to enter S phase and accumulate in G1, leading to an elevated cell death. Rb+/+ cells, but not Rb/, depleted of Ctip are arrested at G1, suggesting that this arrest is RB dependent. Importantly, the life spans of Ctip+/ heterozygotes are shortened by the development of multiple types of tumors, predominantly, large lymphomas. This finding uncovers that CtIP is a key protein in early embryogenesis, and the loss of one allele contributes, in part, to tumor formation.
| MATERIALS AND METHODS |
|---|
|
|
|---|
Cell lines and tissue culture. NIH 3T3, Rb+/+, and Rb/ mouse embryonic fibroblasts (MEF), and Saos-2 and SR5 human osteosarcoma cells were cultured in high-glucose Dulbecco's modified Eagle medium containing 10% fetal bovine serum (FBS) at 37°C in an incubator with 10% CO2.
Construction of targeting vectors and establishing the knockout mouse.
The Ctip gene was isolated by screening a
DASH mouse genomic library derived from the 129/Sv mouse strain (kindly provided by Tom Doetschman, University of Cincinnati), using a 2.7-kb cDNA fragment of human CtIP as probe. A 9.8-kb BamHI fragment of the mouse Ctip gene containing exon 5 was subcloned into the pBluescript SK vector. A SalI site was generated in the middle of exon 5 by site-directed mutagenesis for inserting 1.6 kb of pgkneopA cassette flanked by XhoI sites in antisense orientation. This construct was used to generate ES clones for producing chimeric mice according to procedures described previously (21).
Embryo collection and PCR genotyping. Ctip heterozygotes were used for timed pregnancy experiments. For embryos older than E8.5, the visceral yolk sac was collected and subjected to PCR genotyping. For embryos between E4.5 and E8.5, embryos inside the uterus were fixed in 4% paraformaldehyde, embedded in paraffin, and sectioned. Embryonic tissues stained with Mayer's hematoxylin and eosin (H&E) were microdissected from slides for genotyping. The E3.5 blastocysts were flushed from maternal uterus for analysis. PCR genotyping was performed using the primer A (5'-ACA GGT TAA GAG CAG GAT TGT GTG A-3') and B (5'-ATA TGA AAG GGA ACT CAC TCA GCT C-3'), which flank the exon 5 and generate a 144-bp fragment from the wild-type Ctip, while primer C (5'-TGC ACG AGA CTA GTG AGA CGT GCT A-3'), which resides at PGK promoter, and primer A together generate a 388-bp fragment from the targeted Ctip allele.
In vitro blastocyst culture, BrdU incorporation, immunostaining, and TUNEL assay. Blastocysts were isolated from pregnant females at E3.5, and an outgrowth assay was performed as previously described (24).
For BrdU incorporation, blastocysts were cultured for 1 day and then labeled with BrdU in medium for 6 h. Blastocysts were then fixed and incubated with anti-BrdU antibody (Amersham Biosciences) or rabbit polyclonal anti-CtIP antibody (C21) at 4°C overnight. After three washes in PBS, blastocysts were incubated with fluorescence-conjugated secondary antibody at room temperature for 30 min, followed by DAPI staining. Blastocysts were mounted on slides and examined under fluorescence microscopy (Zeiss Axioplan 2 imaging). Slides were demounted later, and blastocysts were collected and lysed for PCR genotyping.
For phospho-histone H3 immunostaining, blastocysts were collected, fixed, and then incubated with anti-phospho-histone H3 (ser10) antibody (6G3; Cell Signaling Technology). A TUNEL assay (24) was performed on freshly collected and fixed blastocysts, using an in situ cell death detection kit (Roche Applied Science) according to the manufacturer's instructions.
Ctip siRNA construction. A Ctip siRNA expression cassette was constructed by inserting a DNA fragment derived from two annealed synthetic oligonucleotides (5'-GGC GTC ATC TCC GGT ATT TGC TCA AGA GAC AAA TAC CGG AGA TGA CGC CCT TTT TA-3' and 5'-AGC TTA AAA AGG GCG TCA TCT CCG GTA TTT GTC TCT TGA GCA AAT ACC GGA GAT GAC GCC-3') into pBS-U6 vector (37). The BamHI fragment containing the U6-siRNA construct was released and subcloned into pAdTrack vector, which carries a GFP-expressing cassette, resulting in pAd-Ctip-siRNA. The adenovirus was then produced following the protocol as described previously (13). Human CtIP siRNA construct was generated under the regulation of U6 promoter by inserting an oligonucleotide sequence from 2275 to 2295 (GGG AGC AGA CCT TTC TCA GTA) of human CtIP into U6 RNAi vector to form pBS/U6-CtIPi. The RNAi expression cassette was then inserted into a pATG vector (28), which directs GFP expression, and that was named pCtIP-RNAi.
Immunoblotting and FACS analysis. Antibodies against p21 (F5 from Santa Cruz Biotechnology), Rb (Rb245), and CtIP (19E8) were used for Western blotting. Fluorescence-activated cell sorting (FACS) analysis for NIH 3T3 cells infected with CtIP-siRNA or GFP adenovirus was carried out using FACScalibur as instructed by the manufacturer (BD Biosciences).
Histology and immunohistochemistry. Collected tissues were fixed in 4% paraformaldehyde and processed through paraffin embedding following standard procedures. Sections were stained with H&E for histopathological evaluation. Immunostaining was performed following the protocol described in a Vectastain Elite ABC kit (Vector Laboratories, Burlingame, CA). For antigen retrieval, slides were heated for 20 min in 10 mM citrate buffer (pH 6.0) in a microwave oven. The antibodies used were CD45R/B220 (BD Biosciences, San Diego, CA), Mac2 (Cadarlane, Ontario, Canada), and CD3 (DAKO, Carpinteria, CA).
| RESULTS |
|---|
|
|
|---|
|
Inner stem cells of Ctip null blastocysts arrest at G1. To explore the reason why Ctip/ embryos die so early, we employed blastocyst outgrowth in culture as an alternative method to study early developmental event. While 41 cultured Ctip+/+ and Ctip+/ blastocysts gave rise to adherent sheets of trophoblastic giant cells and outgrowth of the inner cell mass, 14 Ctip/ blastocysts showed no outgrowth but retained intact zona pellucida (an example is shown in Fig. 2a), suggesting that Ctip/ blastocysts failed to hatch from the eggshell. We then tested whether the inner cell mass underwent apoptosis by a TUNEL assay (24). On average, the total number of cells per Ctip/ blastocyst was slightly lower than that of the wild type or heterozygotes, whereas the number of dead cells was slightly higher in Ctip/ blastocysts than that of the wild type or heterozygotes. These differences were subtle and may not entirely account for the dramatic phenotype seen in the in vitro blastocyst culture (Fig. 2b). To seek for an additional explanation for the phenotype, we analyzed cell cycle profiles for inner stem cells in blastocysts by BrdU uptake at S phase and by immunostaining with anti-phospho-histone H3 (H3P) antibody at G2 or M phase. Essentially, all the Ctip/ blastocysts failed to incorporate BrdU, while 61% of inner stem cells of the wild type or heterozygotes were labeled with BrdU, suggesting that Ctip/ blastocysts failed to enter S phase (Fig. 2c). However, Ctip/ blastocysts contained numbers of cells at G2 and M phases similar to those of the wild-type or heterozygotes (Fig. 2d). Taken together, these results suggest that Ctip is essential for the S-phase entry in inner stem cells. Without Ctip, these cells are arrested at G1, which may eventually lead to cell death. This phenotype is much severer than those observed in mice with null genotype of Ctbp (14), Brca1 (12, 24), Ikaros (9), or Rb (21), all of which interact with Ctip.
|
|
|
|
|
|
| DISCUSSION |
|---|
|
|
|---|
Ctip interacts with Ctbp (34), Brca1 (42, 46), Ikaros (19), and Rb (8, 27). The Ctip null phenotype is much severer than those observed in mice with null genotype of those interacting partners. Ctip/ embryos die at E4 because the blastocysts fail to enter S phase, leading to an elevated cell death. On the other hand, the Ctbp1 null mice survive 20 days postnatally, while the Ctbp2-null are embryonically lethal at E10.5 (14). Brca1/ or Rb/ mouse embryos die at E6.5 or E14.5 (12, 21, 24), respectively, while Ikaros/ mice are viable (9). Thus, CtIP plays a critical factor in very early embryogenesis.
The role of Ctip in G2/M checkpoint control has been reported previously (23). It was postulated that the interaction between Ctip and BRCA1 is essential for this checkpoint activity. However, whether Ctip plays roles in different cell cycle stage remains unclear. We observed that the depletion of Ctip in MEFs leads to G1 arrest, suggesting an important role of Ctip in G1 regulation. Intriguingly, our recent preliminary results revealed that depletion of Ctip in different cell types generated defects at distinct cell cycle stages, suggesting that the role of Ctip in cell cycle progression may manifest differentially depending on cell status.
On the basis of the result that depletion of Ctip arrested Rb+/+, but not Rb/, MEFs at G1 (Fig. 5), the Rb deficiency, at least in part, mitigates the effect of Ctip deficiency in this cell type. It was previously proposed that CtIP has an adaptor role in connecting Rb family proteins for recruiting corepressor CtBP (27). If this is the case, how this Ctip adaptor counteracts Rb in G1 restraint is intriguing. Since RB plays diverse, but concerted, roles in G1/S transition, CtIP may serve as an adaptor to recruit different factors, which counter Rb action in this context. For example, RB is mainly inactivated through hyperphosphorylation by cyclin D/CDK4/6 and cyclin E/CDK2 complexes at G1/S transition (4); however, why the presence of those kinases capable of hyperphosphorylation of RB is not sufficient for cells to enter S phase when CtIP is depleted is not known. One possible explanation is that CtIP represses the transcription of Cdk inhibitor p21 (22). In the absence of CtIP, p21 becomes derepressed and inhibits Cdk activity, leading to Rb hypophosphorylation as shown in Fig. 3 and 5. However, increased expression of p21 in Rb/ MEF was not observed even when Ctip was depleted, suggesting that activation of p21 expression by Ctip requires Rb. Consistently, Rb has been reported to activate p21 transcription through Sp1 and Sp3 (6). When Rb is not available for transactivation, p21 is not expressed and the repression function of Ctip becomes insignificant. In this regard, Ctip may recruit a repressor to counteract the Rb-mediated coactivation of p21. However, not all the Rb-null cells fail to express p21 (35), suggesting that a much more complicated mechanism for regulating p21 exists.
In addition, active Rb has been shown to repress E2F-regulated S-phase genes, such as MCMs, DNA polymerase subunits, and deoxynucleoside triphosphate synthetic enzymes (25). If Ctip is critical for S-phase entry, such repression by Rb/E2F has to be released by the presence of Ctip. In this situation, Ctip has to recruit activators to remove the repression of Rb. However, there are very few transcriptional processes involved in early blastocyst division, albeit depletion of Ctip renders blastocysts defective in entering S phase. Thus, additional mechanism for CtIP in negatively regulating RB at the G1/S transient may exist.
In addition to the transcriptional repression function, RB also has several functions involving DNA replication and chromatin remodeling (47). DNA replication is initiated at specific chromatin elements referred to as replication origins or replicons, on which origin recognition complex could load and in turn sequentially recruit other replication components, including Cdc6, Cdt1, and Mcm2-7, to assemble the prereplication complex. Initiation of replication is then triggered by kinase activities of cyclin-dependent kinase and Cdc7/Dbf4 and by association of other replication factors at G1/S transition (1). Since RB is able to directly inhibit DNA replication by binding to DNA replication factors such as RFC, MCM7, and DNA polymerase
(29, 36, 39), CtIP may be essential for removing RB from replication origin to release RB restraint for DNA replication and S-phase entry. This possibility is under vigorous investigation.
Besides the synthesis of DNA, it has become clear that the chromatin structure maintaining the epigenetic information is critical for cell cycle progression (26). Immediately before or after replication, a subset of proteins that could modify and remodel the DNA and nucleosomes, such as DNA methyltransferase DNMT1 and chromatin assembly factor CAF1, are recruited in the vicinity of replication fork to alter chromatin domains for a variety of DNA processing, including replication, repair, and recombination (5, 15, 44). RB binds to DNMT1, which may contribute to the repression activity (32). Thus, it is likely that binding of CtIP to RB may be essential for restraining RB from the repression status, although the precise mechanism remains to be elucidated.
Interestingly, the Ctip heterozygous mice succumbed to multiple tumors, predominantly, large lymphomas of both B and T cells (Fig. 6b and c), suggesting that Ctip is a bona fide tumor susceptibility gene. In those tumor cells, they retained the wild-type allele of Ctip (Fig. 7a) and were stained positively with anti-Ctip antibodies (Fig. 7b), indicating that the remaining wild-type allele is active. Thus, the tumor formation in these mice may be attributed to haploid insufficiency of Ctip. This phenomenon has been seen in several cases, including TGFß1 and Dmp1 (16, 40).
It is intriguing why reduction in Ctip expression predisposes mice to tumor formation. Since the interacting partners of Ctip including Rb and BRCA1 as well as Ikaros are tumor susceptibility proteins (21, 41, 43), disturbance of the delicate regulation by reducing the availability of the other significant partner may have a similar consequence in tumorigenesis. For example, reducing Ctip, which counteracts Rb in mediating G1/S progression, will increase active form of Rb and disturb Rb-mediated G1 to S progression. It was reported that expression of a hypophosphorylated form of Rb in mice leads to breast carcinoma, perhaps through reducing apoptosis, with low incidence (17). The G2/M checkpoint defect and the genomic instability resulting from the limited BRCA1/CtIP interaction could also trigger tumorigenesis in principle (23), although Brca1 heterozygous mice rarely have an increased tumor incidence (12, 24; W. H. Lee et al., unpublished). Thus, tumor predisposition in Ctip heterozygotes is not unexpected. However, it is surprising to learn that most Ctip+/ mice developed multiple tumors, predominantly lymphoma, at an age as early as 6 months. Ikaros may mediate the tissue specificity of developing large lymphoma in Ctip heterozygotes, because this transcriptional repressor is a key regulator for lymphocyte development and malignancy (9, 30, 41). Interestingly, the transcriptional repression activity of Ikaros, similar to Rb, is modulated by phosphorylation in G1 (10). CtIP may counteract RB as well as Ikaros to release the restraint at G1. Although the detailed mechanism is waiting for further elucidation, the finding described above uncovers, for the first time, a novel G1/S regulation in that CtIP directly counteracts RB restraint. Disturbing this regulation will lead to severe consequences involving embryonic lethality and tumorigenesis.
| ACKNOWLEDGMENTS |
|---|
This work was supported by grants from the National Institutes of Health (CA 94170 to W.-H.L. and CA 85605 to P.-L.C.) and a postdoctoral fellowship from Susan G. Komen Foundation to F.L.
| FOOTNOTES |
|---|
The first two authors contributed equally to this work. ![]()
| REFERENCES |
|---|
|
|
|---|
2. Boyd, J. M., T. Subramanian, U. Schaeper, M. La Regina, S. Bayley, and G. Chinnadurai. 1993. A region in the C-terminus of adenovirus 2/5 E1a protein is required for association with a cellular phos-phoprotein and important for the negative modulation of T24-ras mediated transformation, tumorigenesis and metastasis. EMBO J. 12:469-478.[Medline]
3. Chinnadurai, G. 2002. CtBP family proteins: more than transcriptional corepressors. BioEssays 25:9-12.
4. Classon, M., and E. Harlow. 2002. The retinoblastoma tumour suppressor in development and cancer. Nat. Rev. Cancer 2:910-917.[CrossRef][Medline]
5. Collins, N., R. A. Poot1, I. Kukimoto, C. García-Jiménez1, G. Dellaire, and P. D. Varga-Weisz1. 2002. An ACF1-ISWI chromatin-remodeling complex is required for DNA replication through heterochromatin. Nat. Genet. 32:627-632.[CrossRef][Medline]
6. Decesse, J. T., S. Medjkane, M. B. Datto, and C. E. Cremisi. 2001. RB regulates transcription of the p21/WAF1/CIP1 gene. Oncogene 20:962-971.[CrossRef][Medline]
7. Dubin, M. J., P. H. Stokes, E. Y. Sum, R. S. Williams, V. A. Valova, P. J. Robinson, G. J. Lindeman, J. N. Glover, J. E. Visvader, and J. M. Matthews. 2004. Dimerization of CtIP, a BRCA1- and CtBP-interacting protein, is mediated by an N-terminal coiled-coil motif. J. Biol. Chem. 279:26932-26938.
8. Fusco, C., A. Reymond, and A. S. Zervos. 1998. Molecular cloning and characterization of a novel retinoblastoma-binding protein. Genomics 51:351-358.[CrossRef][Medline]
9. Georgopoulos, K., M. Bigby, J. H. Wang, A. Molnar, P. Wu, S. Winandy, and A. Sharpe. 1994. The Ikaros gene is required for the development of all lymphoid lineages. Cell 79:143-156.[CrossRef][Medline]
10. Gomez-del Arco, P., K. Maki, and K. Georgopoulos. 2004. Phosphorylation controls Ikaros's ability to negatively regulate the G1-S transition. Mol. Cell. Biol. 24:2797-2807.
11. Goodrich, D. W., N. P. Wang, Y. W. Qian, E. Y. Lee, and W. H. Lee. 1991. The retinoblastoma gene product regulates progression through the G1 phase of the cell cycle. Cell 67:293-302.[CrossRef][Medline]
12. Hakem, R., J. L. de la Pompa, C. Sirard, R. Mo, M. Woo, A. Hakem, A. Wakeham, J. Potter, A. Reitmair, F. Billia, E. Firpo, C. C. Hui, J. Roberts, J. Rossant, and T. W. Mak. 1996. The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. Cell 85:1009-1023.[CrossRef][Medline]
13. He, T. C., S. Zhou, L. T. da Costa, J. Yu, K. W. Kinzler, and B. Vogelstein. 1998. A simplified system for generating recombinant adenoviruses. Proc. Natl. Acad. Sci. USA 95:2509-2514.
14. Hildebrand, J. D., and P. Soriano. 2002. Overlapping and unique roles for C-terminal binding protein 1 (CtBP1) and CtBP2 during mouse development. Mol. Cell. Biol. 22:5296-5307.
15. Hoek, M., and B. Stillman. 2003. Chromatin assembly factor 1 is essential and couples chromatin assembly to DNA replication in vivo. Proc. Natl. Acad. Sci. USA 100:12183-12188.
16. Inoue, K., F. Zindy, D. H. Randle, J. E. Rehg, and C. J. Sherr. 2001. Dmp1 is haplo-insufficient for tumor suppression and modifies the frequencies of Arf and p53 mutations in Myc-induced lymphomas. Genes Dev. 15:2934-2939.
17. Jiang, Z., and E. Zacksenhaus. 2002. Activation of retinoblastoma protein in mammary gland leads to ductal growth suppression, precocious differentiation, and adenocarcinoma. J. Cell Biol. 156:185-198.
18. Knudson, A. G. J. 1971. Mutation and cancer: statistical study of retinoblastoma. Proc. Natl. Acad. Sci. USA 68:820-823.
19. Koipally, J., and K. Georgopoulos. 2002. Ikaros-CtIP interactions do not require C-terminal binding protein and participate in a deacetylase-independent mode of repression. J. Biol. Chem. 277:23143-23149.
20. Koipally, J., A. Renold, J. Kim, and K. Georgopoulos. 1999. Repression by Ikaros and Aiolos is mediated through histone deacetylase complexes. EMBO J. 18:3090-3100.[CrossRef][Medline]
21. Lee, E. Y., C. Y. Chang, N. Hu, Y. C. Wang, C. C. Lai, K. Herrup, W. H. Lee, and A. Bradley. 1992. Mice deficient for Rb are nonviable and show defects in neurogenesis and haematopoiesis. Nature 359:288-294.[CrossRef][Medline]
22. Li, S., P. L. Chen, T. Subramanian, G. Chinnadurai, G. Tomlinson, C. K. Osborne, Z. D. Sharp, and W. H. Lee. 1999. Binding of CtIP to the BRCT repeats of BRCA1 involved in the transcription regulation of p21 is disrupted upon DNA damage. J. Biol. Chem. 274:11334-11338.
23. Li, S., N. S. Ting, L. Zheng, P. L. Chen, Y. Ziv, Y. Shiloh, E. Y. Lee, and W. H. Lee. 2000. Functional link of BRCA1 and ataxia telangiectasia gene product in DNA damage response. Nature 406:210-215.[CrossRef][Medline]
24. Liu, C. Y., A. Flesken-Nikitin, S. Li, Y. Zeng, and W. H. Lee. 1996. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development. Genes Dev. 10:1835-1843.
25. Markey, M. P., S. P. Angus, M. W. Strobeck, S. L. Williams, R. W. Gunawardena, B. J. Aronow, and E. S. Knudsen. 2002. Unbiased analysis of RB-mediated transcriptional repression identifies novel targets and distinctions from E2F action. Cancer Res. 62:6587-6597.
26. McNairn, A. J., and D. M. Gilbert. 2003. Epigenomic replication: linking epigenetics to DNA replication. BioEssays 25:647-656.[CrossRef][Medline]
27. Meloni, A. R., E. J. Smith, and J. R. Nevins. 1999. A mechanism for Rb/p130-mediated transcription repression involving recruitment of the CtBP corepressor. Proc. Natl. Acad. Sci. USA 96:9574-9579.
28. Peng, A., and P. L. Chen. 2003. NFBD1, like 53BP1, is an early and redundant transducer mediating Chk2 phosphorylation in response to DNA damage. J. Biol. Chem. 278:8873-8876.
29. Pennaneach, V., I. Salles-Passador, A. Munshi, H. Brickner, K. Regazzoni, F. Dick, N. Dyson, T. T. Chen, J. Y. Wang, R. Fotedar, and A. Fotedar. 2001. The large subunit of replication factor C promotes cell survival after DNA damage in an LxCxE motif- and Rb-dependent manner. Mol. Cell 7:715-727.[CrossRef][Medline]
30. Rebollo, A., and C. Schmitt. 2003. Ikaros, Aiolos and Helios: transcription regulators and lymphoid malignancies. Immunol. Cell Biol. 81:171-175.[CrossRef][Medline]
31. Riley, D. J., E. Y. Lee, and W. H. Lee. 1994. The retinoblastoma protein: more than a tumor suppressor. Annu. Rev. Cell Biol. 10:1-29.[CrossRef][Medline]
32. Robertson, K. D., S. Ait-Si-Ali, T. Yokochi, P. A. Wade, P. L. Jones, and A. P. Wolffe. 2000. DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat. Genet. 25:338-342.[CrossRef][Medline]
33. Schaeper, U., J. M. Boyd, S. Verma, E. Uhlmann, T. Subramanian, and G. Chinnadurai. 1995. Molecular cloning and characterization of a cellular phosphoprotein that interacts with a conserved C-terminal domain of adenovirus E1A involved in negative modulation of oncogenic transformation. Proc. Natl. Acad. Sci. USA 92:10467-10471.
34. Schaeper, U., T. Subramanian, L. Lim, J. M. Boyd, and G. Chinnadurai. 1998. Interaction between a cellular protein that binds to the C-terminal region of adenovirus E1A (CtBP) and a novel cellular protein is disrupted by E1A through a conserved PLDLS motif. J. Biol. Chem. 273:8549-8552.
35. Sheahan, S., C. O. Bellamy, L. Treanor, D. J. Harrison, and S. Prost. 2004. Additive effect of p53, p21 and Rb deletion in triple knockout primary hepatocytes. Oncogene 23:1489-1497.[CrossRef][Medline]
36. Sterner, J. M., S. Dew-Knight, C. Musahl, S. Kornbluth, and J. M. Horowitz. 1998. Negative regulation of DNA replication by the retinoblastoma protein is mediated by its association with MCM7. Mol. Cell. Biol. 18:2748-2757.
37. Sui, G., C. Soohoo, B. Affar el, F. Gay, Y. Shi, W. C. Forrester, and Y. Shi. 2002. A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. Proc. Natl. Acad. Sci. USA 99:5515-5520.
38. Sum, E. Y., B. Peng, X. Yu, J. Chen, J. Byrne, G. J. Lindeman, and J. E. Visvader. 2002. The LIM domain protein LMO4 interacts with the cofactor CtIP and the tumor suppressor BRCA1 and inhibits BRCA1 activity. J. Biol. Chem. 277:7849-7856.
39. Takemura, M., T. Kitagawa, S. Izuta, J. Wasa, A. Takai, T. Akiyama, and S. Yoshida. 1997. Phosphorylated retinoblastoma protein stimulates DNA polymerase alpha. Oncogene 15:2483-2492.[CrossRef][Medline]
40. Tang, B., E. P. Bottinger, S. B. Jakowlew, K. M. Bagnall, J. Mariano, M. R. Anver, J. J. Letterio, and L. M. Wakefield. 1998. Transforming growth factor-beta1 is a new form of tumor suppressor with true haploid insufficiency. Nat. Med. 4:802-807.[CrossRef][Medline]
41. Wang, J. H., A. Nichogiannopoulou, L. Wu, L. Sun, A. H. Sharpe, M. Bigby, and K. Georgopoulos. 1996. Selective defects in the development of the fetal and adult lymphoid system in mice with an Ikaros null mutation. Immunity 5:537-549.[CrossRef][Medline]
42. Wong, A. K., P. A. Ormonde, R. Pero, Y. Chen, L. Lian, G. Salada, S. Berry, Q. Lawrence, P. Dayananth, P. Ha, S. V. Tavtigian, D. H. Teng, and P. L. Bartel. 1998. Characterization of a carboxy-terminal BRCA1 interacting protein. Oncogene 17:2279-2285.[CrossRef][Medline]
43. Xu, X., K. U. Wagner, D. Larson, Z. Weaver, C. Li, T. Ried, L. Hennighausen, A. Wynshaw-Boris, and C. X. Deng. 1999. Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation. Nat. Genet. 22:37-43.[CrossRef][Medline]
44. Ye, X., A. A. Franco, H. Santos, D. M. Nelson, P. D. Kaufman, and P. D. Adams. 2003. Defective S phase chromatin assembly causes DNA damage, activation of the S phase checkpoint, and S phase arrest. Mol. Cell 11:341-351.[CrossRef][Medline]
45. Yu, X., and R. Baer. 2000. Nuclear localization and cell cycle-specific expression of CtIP, a protein that associates with the BRCA1 tumor suppressor. J. Biol. Chem. 275:18541-18549.
46. Yu, X., L. C. Wu, A. M. Bowcock, A. Aronheim, and R. Baer. 1998. The C-terminal (BRCT) domains of BRCA1 interact in vivo with CtIP, a protein implicated in the CtBP pathway of transcriptional repression. J. Biol. Chem. 273:25388-25392.
47. Zheng, L., and W.-H. Lee. 2002. Retinoblastoma tumor suppressor and genome stability. Adv. Cancer Res. 85:13-50.[Medline]
This article has been cited by other articles:
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| J. Bacteriol. | J. Virol. | Eukaryot. Cell |
|---|
| Microbiol. Mol. Biol. Rev. | Clin. Vaccine Immunol. | All ASM Journals |
|---|